Stocks
ImmunoGen, Inc.IMGN
NASDAQHealthcareBiotechnology$31.23+0.02%
Focused on developing targeted cancer therapeutics using antibody-drug conjugate (ADC) technology, this biopharma has gained investor attention following FDA approval of its lead ovarian cancer drug Elahere. The company's pipeline of next-generation ADCs positions it in the competitive oncology space with potential for expansion into additional solid tumors and hematologic malignancies.
Market Cap: $8.7B52W Range: $3.61 – $31.25
Congressional Interest in ImmunoGen, Inc. (IMGN)
1 member of Congress has disclosed 2 trades in ImmunoGen, Inc. (IMGN), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
1
Sells
1
Who in Congress Is Trading IMGN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-01-09 | Thomas MacArthur | buy | $1K – $15K |
| 2016-12-08 | Thomas MacArthur | sell | $1K – $15K |